Ò»¾º¼¼

English Ò»¾º¼¼¼¯ÍÅÆóÒµÓÊÏä

ÌìÏÂÉúÃü¿ÆÑ§Ç°Ñض¯Ì¬Öܱ¨£¨ËÄ£©

2010Äê-04ÔÂ-18ÈÕ ÈªÔ´£ºmebo

£¨04.12--04.18 / 2010£©
Ò»¾º¼¼¹ú¼Ê¼¯ÍÅ:ÌÕ¹úР

¡¡¡¡ ±¾Öܶ¯Ì¬Ö÷ÒªÓÐÒÔÏÂÄÚÈÝ£ºÎ÷·½¿¹ÐàÂõµÄÑо¿£»ÐÄÔà¸Éϸ°ûÁÆ·¨ÉÐδÀֳɣ»¿Ç¾ÛÌÇ¿ÉÒÔÐÞ¸´ÊÜËðµÄÉñ¾­Ï¸°ûĤ£»¸ßËÙDNA²âÐòÊÖÒÕÕ¹ÏÖ×ªÒÆÖ×ÁöµÄÌØ¶¨ÈªÔ´£»Â̲èÖлîÐÔÎïÖÊEGCG¿Éɨ³ýºÍÔ¤·ÀÓëÍíÄê³Õ´ôÖ¢µÈ¼²²¡ÓйصÄÒì³£ÂѰ׳Á»ý£»ÊÝÅ®º¢³¤´óºó»¼È鰩Σº¦¸ü´ó¡£ÆäÖÐǰÁ½ÌõÌÖÂÛÁËÏÖÔÚÎ÷·½ÔÚÐàÂõºÍ¸Éϸ°ûÖÎÁÆ·½ÃæËù´¦ÌïµØ¡£
1. ÑÓÉ쿵½¡ÉúÃüµÄ;¾¶
¡¾ÕªÒª¡¿
¡¡¡¡×îÐÂÒ»ÆÚ¿ÆÑ§ÔÓÖ¾ÉϵÄһƪÎÄÕÂÌÖÂÛÁËÏÖÔڵĿÉÒÔÑÓÉ쿵½¡ÊÙÃüµÄ;¾¶£¬Ö÷ÒªÊÇÁ½Ìõ£ºÒ»ÊÇ¿ØÖÆÒûʳ£¬Ò»ÊÇͨ¹ýÍ»±ä»ò»¯Ñ§ÒÖÖÆ½µµÍÓªÑø´«¸Ðͨ·µÄ»îÐÔ¡£¶þÕß¿ÉÄÜͨ¹ýÏàËÆµÄ½ø»¯Àú³ÌÖеı£´æ»úÖÆÀ´ÑÓ»ºÐàÂõ¡£

¡¾µãÆÀ¡¿
¡¡¡¡µãÆÀ£ºÏÖÔÚÎ÷·½¿¹ÐàÂõµÄÑо¿»¹ÔÚÑÓ»ºÐàÂõµÄ·Ö×Ó»úÖÆÉÏ×öÎÄÕ£¬²¢Ã»ÓÐÒâʶµ½ÈËÌåÔÙÉúÔÚÕâÄÚÀïµÄÖ÷µ¼×÷Óá£

¡¾Ô­ÎÄժ¼¡¿
Science 16 April 2010: Vol. 328. no. 5976, pp. 321 - 326
Review
Extending Healthy Life Span¡ªFrom Yeast to Humans
Luigi Fontana,1,2,* Linda Partridge,3,* Valter D. Longo4,*
When the food intake of organisms such as yeast and rodents is reduced (dietary restriction), they live longer than organisms fed a normal diet. A similar effect is seen when the activity of nutrient-sensing pathways is reduced by mutations or chemical inhibitors. In rodents, both dietary restriction and decreased nutrient-sensing pathway activity can lower the incidence of age-related loss of function and disease, including tumors and neurodegeneration. Dietary restriction also increases life span and protects against diabetes, cancer, and cardiovascular disease in rhesus monkeys, and in humans it causes changes that protect against these age-related pathologies. Tumors and diabetes are also uncommon in humans with mutations in the growth hormone receptor, and natural genetic variants in nutrient-sensing pathways are associated with increased human life span. Dietary restriction and reduced activity of nutrient-sensing pathways may thus slow aging by similar mechanisms, which have been conserved during evolution. We discuss these findings and their potential application to prevention of age-related disease and promotion of healthy aging in humans, and the challenge of possible negative side effects.

2. ÐÄÔà¸Éϸ°ûÁÆ·¨ÉÐδÀÖ³É
¡¾ÕªÒª¡¿
¡¡¡¡ ×÷ΪÏÖÔÚÉúÃü¿ÆÑ§µÄÑо¿ÈÈÃÅ£¬¸Éϸ°ûÁÆ·¨ÐÞ¸´Æ÷¹ÙµÄÑо¿ÁìÓòÖÐÔ¼ÓÐ1/3ÊÇÓÐÌåÌùÔಡ¸Éϸ°ûÁÆ·¨µÄ¡£Ò»Æª½ÒÏþÔÚ×îÐÂÒ»ÆÚScience Translational MedicineµÄÎÄÕÂ×ܽá˵£¬ºã¾ÃµÄÐÄÔಡ¸Éϸ°ûÁÆ·¨ÁÙ´²ÊÔÑéЧ¹ûÁîÈËʧÍû¡£²¿·ÖÔµ¹ÊÔ­ÓÉÊǸÉϸ°ûÖÎÁƵÄÁÙ´²Ç°ÊÔÑéûÄÜÀÖ³ÉÓÅ»¯¸Éϸ°ûµÄÔËËÍÊýÄ¿£¬×î¼ÑÔËËÍʱ¼ä£¬ÔËËÍÀàÐͺÍÔËËÍÊÖÒÕ£¬Ò²Ã»ÄÜÚ¹ÊÍÐÄ˥ʱÐÎ̬ת±äµÄÔµ¹ÊÔ­ÓÉ¡£ ÔÚרÐļ¡Ï¸°û¾ÙÐеÄϸ°ûÖÎÁÆÖУ¬ËùÓÃϸ°ûûÄÜʵÏÖ׼ȷ¶¨Î»²¢ÓëÖ÷Ìå×éÖ¯Èںϡ£ÎÄÕÂ×ܽáÆÊÎöÁËÏÖÔÚÖ±½ÓÔËË͸Éϸ°û»ò¸Éϸ°ûÑÜ»¯À´µÄÐļ¡Ï¸°ûµ½ÐÄÔàµÄϸ°ûÁÆ·¨µÄÑо¿Ì¬ÊƺÍÃæÁÙµÄÖÖÖÖÌôÕ½¡£

¡¾µãÆÀ¡¿
¡¡¡¡µãÆÀ£º±¾ÎÄÊÇÖ÷Á÷ÉúÃü¿ÆÑ§½ç×Ô¼ºËù×öµÄ×ܽáÆÊÎö£¬ËµÃ÷ËûÃǵĸÉϸ°ûÁÆ·¨ÖÁÉÙÊÇÐÄÔಡµÄ¸Éϸ°ûÖÎÁƵÄÁÙ´²ÊÔÑéÊÇʧ°ÜµÄ£¬ÃæÁÙµÄÄÑÌâºÜ´ó£¬ÌôÕ½Ðí¶à£¬ÀֳɵÄÏ£Íû²»´ó¡£¼ò¶øÑÔÖ®£¬²»ÖªµÀ»úÌåÔõÑùµ÷¿Ø×ÔÉí¸Éϸ°ûÐÞ¸´Æ÷¹Ù£¬¾ÍºÜÄÑÈ¥È˹¤¸´ÖÆÕâÒ»Àú³Ì¡£

¡¾Ô­ÎÄժ¼¡¿
Sci Transl Med 14 April 2010: Vol. 2,Issue 27,p. 27ps17 DOI: 10.1126/scitranslmed.3000558
Challenges in Using Stem Cells for Cardiac Repair
Christine L. Mummery1,*, Richard P. Davis1 and Jose E. Krieger2
Of the many diseases discussed in the context of stem cell therapy, those concerning the heart account for almost one-third of the publications in the field. However, the long-term clinical outcomes have been disappointing, in part because of preclinical studies failing to optimize the timing, number, type, and method of cell delivery and to account for shape changes that the heart undergoes during failure. In situations in which cardiomyocytes have been used in cell therapy, their alignment and integration with host tissue have not been realized. Here we review the present status of direct delivery of stem cells or their derivative cardiomyocytes to the heart and the particular challenges each cell type brings, and consider where we should go from here.

3. ¿Ç¾ÛÌÇ¿ÉÒÔÐÞ¸´ÊÜËðµÄÉñ¾­Ï¸°ûĤ
¡¾ÕªÒª¡¿
¡¡¡¡BorgensÑо¿×é·¢Ã÷£¬¿Ç¾ÛÌÇ¿ÉÒÔÐÞ¸´ÊÜËðµÄÉñ¾­Ï¸°ûĤ¡£×î³õ²âÊÔÁ˸ʶÌÇ£¬Ð§¹û·¢Ã÷Ëü²»¿ÉÐÞ¸´¼¹ËèÉñ¾­Ï¸°ûĤ£¬ÓÚÊǾöÒé²âÊԿǾÛÌÇ£¬Ð§¹û·¢Ã÷¿Ç¾ÛÌÇÐÞ¸´ÁËÊÜËðµÄϸ°ûĤ¡£²»Ö¹ÔÆÔÆ£¬½øÒ»²½µÄ²âÊÔ·¢Ã÷¿Ç¾ÛÌÇ¿ÉÄܼÈÐÞ¸´ÁËÉñ¾­Ï¸°ûĤ£¬ÓÖÐÞ¸´ÁËÏßÁ£ÌåĤ¡£ ²¢ÇҿǾÛÌÇÓÐÄÜÁ¦ÐÞ¸´ÊÜËðµÄ¼¹Ë裬´Ó¶øÈÃËüÄܹ»°Ñ¶¯ÎïÉíÌåµÄÐźÅת´ï¸ø´óÄÔ¡£Borgens¹ØÓÚÕâÏî¿Ç¾ÛÌÇÓÐÄÜÁ¦¶¨Î»²¢ÐÞ¸´ÊÜËð¼¹Ëè×éÖ¯µÄ·¢Ã÷¼«ÎªÐË·Ü£¬²¢ÇÒËû¹ØÓڿǾÛÌǵÄÄÉÃ׿ÅÁ£¿ÉÄÜÓÐÕë¶ÔÐÔµØÖ±½ÓÏòÊÜËðÇøÓò¹©Ó¦Éñ¾­±£»¤Ò©ÎïµÄ¡°Ë«ÖØÊÕÒæ¡±µÄÔ¶¾°Ô½·¢³äÂúÈÈÇé¡£
ȪԴ£º¡¶ÊµÑéÉúÎïѧÔÓÖ¾¡·

¡¾µãÆÀ¡¿
¡¡¡¡µãÆÀ£º¿Ç¾ÛÌÇÊÇ×ÔÈ»½çΨһ´øÕýµçºÉµÄ¶àÌÇ£¬ÕâÒ»ÌØÕ÷ºÜ¿ÉÄÜÓëËüÄܹ»¶¨Î»ÔÚÊÜËðÉñ¾­Ï¸°ûĤÉÏÓйØ¡£ ×ÔÈ»²úÆ·¿Ç¾ÛÌÇÓÐÄÜÁ¦¶¨Î»²¢ÐÞ¸´ÊÜËð¼¹Ëè×éÖ¯µÄ·¢Ã÷ÒÔ¼°ÒòÆä¶¨Î»ÄÜÁ¦¶øÀ´µÄ¿ÉÄÜÓÐÕë¶ÔÐÔµØÖ±½ÓÏòÊÜËðÇøÓò¹©Ó¦Éñ¾­±£»¤Ò©ÎïµÄ¡°Ë«ÖØÊÕÒæ¡±µÄÔ¶¾°¹ØÓÚÒ©ÎïÖÎÁÆÉñ¾­ËðÉËÊǸö¸£Òô¡£

¡¾Ô­ÎÄժ¼¡¿
Journal of Experimental Biology 213, 1513-1520 (2010£©doi: 10.1242/jeb.035162
Chitosan produces potent neuroprotection and physiological recovery following traumatic spinal cord injury
Youngnam Cho1,*, Riyi Shi1,2 and Richard B. Borgens1,2
Chitosan, a non-toxic biodegradable polycationic polymer with low immunogenicity, has been extensively investigated in various biomedical applications. In this work, chitosan has been demonstrated to seal compromised nerve cell membranes thus serving as a potent neuroprotector following acute spinal cord trauma. Topical application of chitosan after complete transection or compression of the guinea pig spinal cord facilitated sealing of neuronal membranes in ex vivo tests, and restored the conduction of nerve impulses through the length of spinal cords in vivo, using somatosensory evoked potential recordings. Moreover, chitosan preferentially targeted damaged tissues, served as a suppressor of reactive oxygen species (free radical) generation, and the resultant lipid peroxidation of membranes, as shown in ex vivo spinal cord samples. These findings suggest a novel medical approach to reduce the catastrophic loss of behavior after acute spinal cord and brain injury.

4. ¸ßËÙDNA²âÐòÊÖÒÕÕ¹ÏÖ×ªÒÆÖ×ÁöµÄÌØ¶¨ÈªÔ´
¡¾ÕªÒª¡¿
¡¡¡¡ ÏÖÔÚDNA²âÐòÊÖÒÕ¸ßËÙÉú³¤£¬Òò´ËÓпÉÄܶÔÕû¸öÒ»¸ö»ùÒò×é¾ÙÐÐɸѡ£¬ÒÔѰÕÒÓëÖ×ÁöÏ£ÍûÏà¹ØµÄ»ùÒòת±ä¡£»ªÊ¢¶Ù´óѧµÄÑо¿Ö°Ô±Ê¹ÓÃ×îеIJâÐòÊÖÒÕ¶ÔһλÈéÏÙ°©»¼ÕßµÄËĸöDNAÑù±¾µÄÍêÕûÐòö¾ÙÐÐÁËÐòÁÐÆÊÎö£¬´ÓÖз¢Ã÷×ªÒÆÖ×ÁöÌØ¶¨Ñ¡ÔñÀ´×ÔÔ­·¢ÐÔÖ×ÁöÖÐÒµÒѱ£´æÍ»±äµÄÒ»¸öÑÇȺϸ°û£¬²¢ÇÒ»¹»áÐγÉÉÙÁ¿ÐÂÍ»±ä¡£ ´Ë´Î²âÐòÊÂÇéÕ¹ÏÖÁËÏÕЩËùÓÐDZÔÚµÄÖ°©È¾É«ÌåÒ×λ¼°µ¼Ö¸ð©Ö¢Éú³¤µÄ»ùÒòȱʧºÍÍ»±ä¡£

¡¾µãÆÀ¡¿
¡¡¡¡µãÆÀ£º¸ÃÏîÑо¿µÄ×î´óÒâÒå²»ÔÚÓÚ¶ÔÆÊÎö°©Ö¢±¬·¢ÆøÖƶà´óТ˳£¬¶øÊÇʵ¼ùÁË×îеĸßËÙDNA²âÐòÊÖÒÕ£¬¹ØÓÚÕï¶ÏÉϵÄÒâÒå¿ÉÄܸü´ó£¬ÓÐÖúÓÚ°©Ö¢Ô¤·À¡£

¡¾Ô­ÎÄժ¼¡¿
Nature 464, 999-1005 (15 April 2010) doi:10.1038/nature08989
Genome remodelling in a basal-like breast cancer metastasis and xenograf
Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primary tumour. The metastasis contained two de novo mutations and a large deletion not present in the primary tumour, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumour mutations and displayed a mutation enrichment pattern that resembled the metastasis. Two overlapping large deletions, encompassing CTNNA1, were present in all three tumour samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour.

5. Â̲èÖлîÐÔÎïÖÊEGCG¿Éɨ³ýºÍÔ¤·ÀÓëÍíÄê³Õ´ôÖ¢µÈ¼²²¡ÓйصÄÒì³£ÂѰ׳Á»ý
¡¾ÕªÒª¡¿
¡¡¡¡ Ò»Ïî×îÐÂÑо¿Ð§¹ûÏÔʾ£¬Â̲èÖлîÐÔÎïÖÊEGCG¿Éɨ³ýÓëÍíÄê³Õ´ôÖ¢µÈ¼²²¡ÓйصÄÂѰ×ÖÊÒì³£³Á»ý´øÀ´µÄ¶¾ÐÔ¡£¦Âµí·ÛÑùÂѰ×ÊÇÓÉÂѰ×ÖʵĹýʧÕÛµþµ¼ÖµÄ£¬¦Âµí·ÛÑùÂѰ×Òì³£³Á»ýÊÇÍíÄê³Õ´ôÖ¢ºÍÅÁ½ðÉ­ÊÏÖ¢µÈ¼²²¡µÄÖ÷Òª²¡Òò¡£µÂ¹úÂí¿Ë˹•µÂ¶û²¼ÂÀ¿Ë·Ö×ÓҽѧÖÐÐÄÑо¿Ö°Ô±ÔÚÊԹܺÍϸ°û×÷Óý»ùʵÑéÖз¢Ã÷£¬Ö²ÈëÕâÖÖÓж¾ÂѰ׳Á»ý»áµ¼ÖÂÉñ¾­Ï¸°ûг´úлˮƽϽµ£¬Ï¸°ûĤҲ»á±äµÃ²»ÎȹÌ¡£¶øÒ»µ©ÓÐÂ̲è»îÐÔÎïÖÊEGCG½éÈ룬ÕâЩϸ°ûÊÜËðµÄÕ÷Ïó»áÏûÊÅ¡£EGCG½â¶¾×÷ÓõĻúÀíÊÇÆäÊ×ÏÈÓëÏËά״¦Âµí·ÛÑùÂѰ×͎ᣬ½«ºóÕßתÄð³É¶ÔÉñ¾­Ï¸°ûÎÞº¦¡¢Ö®ºóÓֻᱻϸ°ûÆÊÎöµÄÇò×´ÂѰ׾ÛÕûÌå¡£Ëü»¹Äܹ»Ó뻹ûÓÐÕÛµþµÄÂѰ×ÖÊ͎ᣬ×èÖ¹Æä¹ýʧÕÛµþ£¬´Ó¶ø×èÖ¹ÓëÍíÄê³Õ´ôÖ¢¡¢ÅÁ½ðÉ­ÊÏÖ¢ºÍºàÍ¢¶ÙÎ赸²¡ÓйصÄÂѰ׳Á»ýµÄÐγÉ¡£

¡¾µãÆÀ¡¿
¡¡¡¡µãÆÀ£ºÂ̲èµÄ±£½¡¹¦Ð§ÓÖ¶àÁËÒ»ÏÓпÉÄÜÔ¤·À»ººÍ½âÓëÒì³£ÂѰ׳Á»ýÓйصÄÍíÄê³Õ´ôÖ¢¡¢ÅÁ½ðÉ­ÊÏÖ¢ºÍºàÍ¢¶ÙÎ赸²¡µÈ¼²²¡¡£Òªº¦ÊÇ¿´EGCGÄÜ·ñͨ¹ýѪÄÔÆÁÕÏ¡£

¡¾Ô­ÎÄժ¼¡¿
PNAS April 12, 2010, doi: 10.1073/pnas.0910723107
EGCG remodels mature ¦Á-synuclein and amyloid-¦Â fibrils and reduces cellular toxicity
Jan Bieschke1, Jenny Russ, Ralf P. Friedrich, Dagmar E. Ehrnhoefer2, Heike Wobst, Katja Neugebauer, and Erich E. Wanker1
Protein misfolding and formation of ¦Â-sheet-rich amyloid fibrils or aggregates is related to cellular toxicity and decay in various human disorders including Alzheimer¡¯s and Parkinson¡¯s disease. Recently, we demonstrated that the polyphenol (-)-epi-gallocatechine gallate (EGCG) inhibits ¦Á-synuclein and amyloid-¦Â fibrillogenesis. It associates with natively unfolded polypeptides and promotes the self-assembly of unstructured oligomers of a new type. Whether EGCG disassembles preformed amyloid fibrils, however, remained unclear. Here, we show that EGCG has the ability to convert large, mature ¦Á-synuclein and amyloid-¦Â fibrils into smaller, amorphous protein aggregates that are nontoxic to mammalian cells. Mechanistic studies revealed that the compound directly binds to ¦Â-sheet-rich aggregates and mediates the conformational change without their disassembly into monomers or small diffusible oligomers. These findings suggest that EGCG is a potent remodeling agent of mature amyloid fibrils.

6. ÊÝÅ®º¢³¤´óºó»¼È鰩Σº¦¸ü´ó
¡¾ÕªÒª¡¿ ÐÂÀË¿µ½¡ 2010-4-16 13:51:23
¡¡¡¡Èðµä˹µÂ¸ç¶ûĦ¿¨ÂÞÁÖ˹¿¨Ò½Ñ§ÔºµÄÑо¿·¢Ã÷£¬ÏûÊݵÄÅ®º¢ÈÕºó¸üÓпÉÄÜ»¼ÉÏÈé°©¡£ÓëСʱ¼ä½ÏÅÖµÄÅ®º¢Ïà±È£¬7ËêʱÉí¶Î½ÏÊݵÄÅ®º¢³¤´óºó»¼Èé°©µÄΣº¦¸ü´ó¡£¿ÆÑ§¼Ò»¹·¢Ã÷£¬Ð¡Ê±¼äÉÔÅÖµÄÅ®º¢ÔÖ»öÒÔ¹¥¿ËµÄÖ×ÁöµÄ¸ÅÂʽÏС¡£Ñо¿Îª°ÑͯÄêʱ¾ÉÕÕÆ¬×÷ΪÆÀ¹ÀÅ®ÐÔÈ鰩Σº¦µÄÒªÁìÆÌƽÁËõè¾¶¡£Ð¡Ê±¼ä½ÏÅÖµÄÅ®ÐÔ¾ø¾­ÆÚ»¼Èé°©µÄΣº¦½ÏС¡£Ö®Ç°µÄÑо¿ÏÔʾ£¬·ÊÅÖµÄÅ®ÐÔ¸üÒ×»¼Èé°©£¬²¢ÇÒËýÃÇËÀÓÚÈé°©µÄΣº¦¸ß´ï50%¡£ ¿ÆÑ§¼Ò²»È·¶¨ÊÝÅ®º¢Ò×»¼Èé°©µÄÔµ¹ÊÔ­ÓÉÊÇʲô¡£ËûÃÇÌåÏÖ£¬Ð·¢Ã÷¿ÉÄܶÔÅжÏÅ®ÐÔÈ鰩Σº¦¾ßÓÐÖ÷ÒªÒâÒå¡£

¡¾µãÆÀ¡¿
¡¡¡¡µãÆÀ£ºÕâ¸öÓëÒÔǰÊìϤ²î±ðµÄ·¢Ã÷×ÅʵÊÇÓÐÆäºÏÀíÐԵ쬰©Ö¢µÄÔ¤·ÀÓëÉíÌåÃâÒßϵͳ¹ØÏµÇ×½ü£¬¶øÔ½À´Ô½¶àµÄÑо¿Åú×¢ÈËÌåÖ¬·¾×éÖ¯ÓëÃâÒßϵͳ¿ÉÄÜÓкܴó¹ØÏµ£¬ÔÚÐγÉ×ÔÉí³ÉÊìÃâÒßϵͳµÄÉÙ¶ùÆÚ£¬ÉíÌåÖ¬·¾Ïà¶Ô¸»×ãһЩ¿ÉÄÜÓÐÀûÓÚ¸üºÃµÄ³É¼¨×ÔÉíÃâÒßϵͳ¡£

¡¾Ô­ÎÄժ¼¡¿
Breast Cancer Research 2010, 12:R23 | doi:10.1186/bcr2564
Effects of childhood body size on breast cancer tumour characteristics
Jingmei Li , Keith Humphreys , Louise Eriksson , Kamila Czene , Jianjun Liu and Per Hall
Introduction
Although a role of childhood body size in postmenopausal breast cancer risk has been established, less is known about its influence on tumour characteristics.
Methods
We studied the relationships between childhood body size and tumour characteristics in a Swedish population-based case-control study consisting of 2,818 breast cancer cases and 3,111 controls. Our classification of childhood body size was derived from a nine-level somatotype. Relative risks were estimated by odds ratios with 95% confidence intervals, derived from fitting unconditional logistic regression models. Association between somatotype at age 7 and tumour characteristics were evaluated in a case-only analysis where P-values for heterogeneity were obtained by performing one degree of freedom trend tests.
Results
A large somatotype at age 7 was found to be associated with decreased postmenopausal breast cancer risk. Although strongly associated with other risk factors such as age of menarche, adult body mass index and mammographic density, somatotype at age 7 remained a significant protective factor (odds ratio (OR) comparing large to lean somatotype at age 7 = 0.73, 95% confidence interval (CI) = 0.58-0.91, P trend = 0.004) after adjustment. The significant protective effect was observed within all subgroups defined by estrogen receptor (ER) and progesterone receptor (PR) status, with a stronger effect for ER-negative (0.40, 95% CI = 0.21-0.75, P trend = 0.002), than for ER-positive (0.80, 95% CI = 0.62-1.05, P trend = 0.062), tumours (P heterogeneity = 0.046). Somatotype at age 7 was not associated with tumour size, histology, grade or the presence or absence of metastatic nodes.
Conclusions
Greater body size at age 7 is associated with a decreased risk of postmenopausal breast cancer, and the associated protective effect is stronger for the ER-negative breast cancer subtype than for the ER-positive subtype.
 

ÍøÕ¾µØÍ¼